377 related articles for article (PubMed ID: 32088096)
41. Prediction of fast decline in amyloid positive mild cognitive impairment patients using multimodal biomarkers.
Jang H; Park J; Woo S; Kim S; Kim HJ; Na DL; Lockhart SN; Kim Y; Kim KW; Cho SH; Kim SJ; Seong JK; Seo SW;
Neuroimage Clin; 2019; 24():101941. PubMed ID: 31376643
[TBL] [Abstract][Full Text] [Related]
42. Association of Subjective Cognitive Decline with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study.
Wen C; Bi YL; Hu H; Huang SY; Ma YH; Hu HY; Tan L; Yu JT
J Alzheimers Dis; 2022; 85(3):1143-1151. PubMed ID: 34924386
[TBL] [Abstract][Full Text] [Related]
43. Network Disruption and Cerebrospinal Fluid Amyloid-Beta and Phospho-Tau Levels in Mild Cognitive Impairment.
Canuet L; Pusil S; López ME; Bajo R; Pineda-Pardo JÁ; Cuesta P; Gálvez G; Gaztelu JM; Lourido D; García-Ribas G; Maestú F
J Neurosci; 2015 Jul; 35(28):10325-30. PubMed ID: 26180207
[TBL] [Abstract][Full Text] [Related]
44. Cerebrospinal fluid biomarkers of Alzheimer's disease are associated with carotid plaque score and hemodynamics in intra- and extra-cranial arteries on ultrasonography.
Kouzuki M; Nagano M; Suzuki T; Katsumata Y; Nakamura S; Takamura A; Urakami K
J Clin Neurosci; 2018 Mar; 49():32-36. PubMed ID: 29249541
[TBL] [Abstract][Full Text] [Related]
45. CSF lactate levels, τ proteins, cognitive decline: a dynamic relationship in Alzheimer's disease.
Liguori C; Stefani A; Sancesario G; Sancesario GM; Marciani MG; Pierantozzi M
J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):655-9. PubMed ID: 25121572
[TBL] [Abstract][Full Text] [Related]
46. The relation of a cerebrospinal fluid profile associated with Alzheimer's disease with cognitive function and neuropsychiatric symptoms in sporadic cerebral amyloid angiopathy.
De Kort AM; Kaushik K; Kuiperij HB; Jäkel L; Li H; Tuladhar AM; Terwindt GM; Wermer MJH; Claassen JAHR; Klijn CJM; Verbeek MM; Kessels RPC; Schreuder FHBM
Alzheimers Res Ther; 2024 May; 16(1):99. PubMed ID: 38704569
[TBL] [Abstract][Full Text] [Related]
47. Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease.
Alexopoulos P; Werle L; Roesler J; Thierjung N; Gleixner LS; Yakushev I; Laskaris N; Wagenpfeil S; Gourzis P; Kurz A; Perneczky R;
Alzheimers Res Ther; 2016 Dec; 8(1):51. PubMed ID: 27931251
[TBL] [Abstract][Full Text] [Related]
48. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.
Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A
J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653
[TBL] [Abstract][Full Text] [Related]
49. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
[TBL] [Abstract][Full Text] [Related]
50. Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes.
van Waalwijk van Doorn LJ; Gispert JD; Kuiperij HB; Claassen JA; Arighi A; Baldeiras I; Blennow K; Bozzali M; Castelo-Branco M; Cavedo E; Emek-Savaş DD; Eren E; Eusebi P; Farotti L; Fenoglio C; Ormaechea JF; Freund-Levi Y; Frisoni GB; Galimberti D; Genc S; Greco V; Hampel H; Herukka SK; Liu Y; Lladó A; Lleó A; Nobili FM; Oguz KK; Parnetti L; Pereira J; Picco A; Pikkarainen M; de Oliveira CR; Saka E; Salvadori N; Sanchez-Valle R; Santana I; Scarpini E; Scheltens P; Soininen H; Tarducci R; Teunissen C; Tsolaki M; Urbani A; Vilaplana E; Visser PJ; Wallin AK; Yener G; Molinuevo JL; Meulenbroek O; Verbeek MM
J Alzheimers Dis; 2017; 56(2):543-555. PubMed ID: 28059783
[TBL] [Abstract][Full Text] [Related]
51. Usefulness of CSF Biomarkers in Predicting the Progression of Amnesic and Nonamnesic Mild Cognitive Impairment to Alzheimer's Disease.
Ortega RL; Dakterzada F; Arias A; Blasco E; Naudí A; Garcia FP; Piñol-Ripoll G
Curr Aging Sci; 2019; 12(1):35-42. PubMed ID: 31589110
[TBL] [Abstract][Full Text] [Related]
52. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G
J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522
[TBL] [Abstract][Full Text] [Related]
53. Combined Biomarker Prognosis of Mild Cognitive Impairment: An 11-Year Follow-Up Study in the Alzheimer's Disease Neuroimaging Initiative.
Spencer BE; Jennings RG; Brewer JB;
J Alzheimers Dis; 2019; 68(4):1549-1559. PubMed ID: 30958366
[TBL] [Abstract][Full Text] [Related]
54. The Latent Dementia Phenotype δ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment.
Koppara A; Wolfsgruber S; Kleineidam L; Schmidtke K; Frölich L; Kurz A; Schulz S; Hampel H; Heuser I; Peters O; Reischies FM; Jahn H; Luckhaus C; Hüll M; Gertz HJ; Schröder J; Pantel J; Rienhoff O; Rüther E; Henn F; Wiltfang J; Maier W; Jessen F; Kornhuber J; Wagner M
J Alzheimers Dis; 2016; 49(2):547-60. PubMed ID: 26484902
[TBL] [Abstract][Full Text] [Related]
55. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A
Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314
[TBL] [Abstract][Full Text] [Related]
56. Is cerebral microbleed prevalence relevant as a biomarker in amnestic mild cognitive impairment and mild Alzheimer's disease?
Rabelo AG; Teixeira CV; Magalhães TN; Carletti-Cassani AFM; Amato Filho AC; Joaquim HP; Talib LL; Forlenza O; Ribeiro PA; Secolin R; Lopes-Cendes I; Cendes F; Balthazar ML
Neuroradiol J; 2017 Oct; 30(5):477-485. PubMed ID: 28714354
[TBL] [Abstract][Full Text] [Related]
57. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
Podhorna J; Krahnke T; Shear M; Harrison JE;
Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
[TBL] [Abstract][Full Text] [Related]
58. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
[TBL] [Abstract][Full Text] [Related]
59. The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease.
Hohman TJ; Bell SP; Jefferson AL;
JAMA Neurol; 2015 May; 72(5):520-9. PubMed ID: 25751166
[TBL] [Abstract][Full Text] [Related]
60. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
Seppälä TT; Koivisto AM; Hartikainen P; Helisalmi S; Soininen H; Herukka SK
J Alzheimers Dis; 2011; 25(4):583-94. PubMed ID: 21460434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
